Nice work @daveironore!
Because proteinuria is such a salient feature of FSGS, because it’s a disease without any formal treatment, because the patients can be easily found within hospital databases, because it can be designated orphan status...several reasons for it to be targeted originally.
But, and I can’t be bothered going back to whenever I first posted about diabetics, the patho-pharmaco-physiology matches up like you wouldn’t believe. As I was reading and researching deeper, it just made sense, given all the recent research into diabetic nephropathology.
As an aside, I’ve delved into NASH and propagermanium. The same set of enzymes crop up time and again.
(I haven’t yet looked into the eye issue nor the MS stuff)
Ann: Ethics Committee Approval for Pharmacokinetic Trial, page-14
-
- There are more pages in this discussion • 74 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add DXB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
45.5¢ |
Change
0.045(11.0%) |
Mkt cap ! $253.4M | |||
| Open | High | Low | Value | Volume |
| 41.5¢ | 46.5¢ | 41.0¢ | $3.375M | 7.571M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 149191 | 44.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 45.5¢ | 195819 | 4 |
View Market Depth
| Last trade - 16.10pm 10/10/2024 (20 minute delay) ? |
| DXB (ASX) Chart |